# Fixed feedback review

All 24 responses reviewed against saved public artifacts. Model outputs remain unchanged. Categories B–E are conservative confirmed failure flags; additional ambiguities and mixed concerns are described rather than promoted to certain errors.

## P1 — private_target_counts

Saved da-13-6/rep-002/s000. Decision **revise**, 3 concerns. Flags: D.

No private protein examples or expected concordance conclusion. Issue 1 nevertheless says missingness and retained dimensions are not computed/displayed, despite shape/isna prints and the reported output. Issue 3 treats canonical file sections as insufficient creation evidence; this is an unnecessary workspace-verification demand, not proof files were absent.

Requests checkable intermediate accounting; multiplicity/exploratory framing is a plausible verification topic, though not proof the existing biological conclusion is wrong.

Public source spans: 24–35, 98–111. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The trace does not provide actual code for the reported data-quality checks and intermediate counts: Step 1 only shows loading and summary calls, while the stated raw-row counts, retained dimensions, zero-missingness result, and merge retention are not reproducibly computed or displayed by the snippets. Add executable code that prints those exact quantities (including raw and retained row counts and merge overlap) and record its outputs.

> The analysis reports nominal Spearman p-values for ten correlated comparator-by-regimen tests and interprets several tiny p-values as evidence of similarity, but does not adjust these newly computed correlation tests for multiplicity. Add a prespecified multiple-testing correction (or clearly label these p-values exploratory) and report adjusted values, while retaining effect sizes and uncertainty.

> The artifact combines the trace and answer content but does not demonstrate that the required separate output files `/app/trace.md` and `/app/answer.txt` were created. Please verify both files exist at those exact paths and contain the corresponding sections/content.

## P1 — different_populations

Saved da-13-6/rep-003/s002. Decision **revise**, 1 concerns. Flags: C.

Correctly drops the numerical contradiction candidate, but issue 3 incorrectly imports the exploratory composite requirement of an available adjusted p-value into the primary fixed-stratum rule, which explicitly needs only an available MHT estimate.

No false 109-versus-212 arithmetic allegation survives; the remaining concern is a scope error.

Public source spans: 97–120, 122–140. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The fixed-stratum code filters availability only on the MHT estimate (`estimate_MHT...notna()`), while the stated comparison requires an available estimate and adjusted p-value. Verify that the reported denominators and same/opposite counts exclude rows with missing MHT adjusted p-values, and recompute if necessary; otherwise the code and reported results are not fully reproducible from the documented rule.

## P1 — coefficient_coding_sign

Saved da-15-1/rep-002/s001. Decision **revise**, 3 concerns. Flags: none confirmed.

Does not repeat the sign-reversal allegation. Two separate renders duplicate the real scalar-WLS/count-model mismatch. The proteomics demand overstates a background dataset description as an explicit requirement; actual file availability is unresolved in this public packet.

Identifies constant per-gene weights on log expression and unused off; a scalar WLS weight cancels, so this is not the claimed NB fit. A full package-only remedy is not established as the only valid implementation.

Public source spans: 53–81, 92–116. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The revised method is still not a valid negative-binomial GLM: it estimates one scalar dispersion and weight per gene, applies that constant weight to every sample, then fits WLS to log-transformed normalized counts. It also defines `off` but never uses a count-model offset. Please either implement a genuine edgeR/DESeq2-style NB GLM (including fitted means, dispersion estimation, and likelihood-based tests) or describe this explicitly as an approximate weighted log-expression analysis and avoid presenting the results as count-model inference; then recompute and report the results accordingly.

> The trace does not include the required explicit **Data Sources**, **Approach**, and **Results** details for the proteomics dataset described in the task, nor does it document its dimensions, key columns, or data-quality notes. It says no proteomics file was present, but the task identifies proteomics as part of the supplied dataset; verify the available files and either analyze the protein data for orthogonal validation or clearly document the verified absence and resulting limitation.

> The reported model is not actually a negative-binomial GLM with library-size offsets: it fits log2 normalized counts by WLS using one scalar, gene-level method-of-moments weight, and an unadjusted residual scale. The code also defines `off` but never uses it. Please either implement and describe a valid edgeR/DESeq2-style NB model (including dispersion estimation and offset handling) or relabel this as an approximate weighted log-expression model and avoid presenting its p-values/FDRs as count-model inference; then recompute the reported statistics and DEG counts accordingly.

## P1 — unavailable_remedy

Saved da-15-1/rep-003/s003. Decision **revise**, 3 concerns. Flags: none confirmed.

Keeps a real missing sensitivity-script concern, twice. Reanalysis request is conditional on package feasibility and recognizes the conflict between public task installation permission and artifact-reported prohibition. The claim that diagnostic code is absent is overbroad: a quantile print is shown, while captured numeric outputs are missing.

Local executable sensitivity code/captured outputs are useful even if the preferred package is unavailable.

Public source spans: 41–67, 75–107, 121–150. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The trace still does not provide executable code for the reported sensitivity analyses or for the package audit/dispersion diagnostics: it refers to an external `sensitivity.py`, gives only a text summary, and comments out the R audit command. Include the actual runnable scripts/commands and captured outputs needed to reproduce the reported dimensions, DEG counts, rankings, and package-availability claims.

> The reported DEGs still come from custom method-of-moments WLS rather than a validated RNA-seq framework, and the package audit is not sufficient evidence that installation was prohibited: the task explicitly says additional packages may be installed and internet access is available. Install/use DESeq2, edgeR, or limma-voom if possible, then recompute all reported counts, FDRs, fold changes, rankings, and sensitivities; otherwise document the actual installation attempt and treat the current results only as an incomplete exploratory fallback.

> The reported sensitivity results are not independently reproducible from the trace: it names `sensitivity.py` and output files but does not include the script or executable code for constructing those designs, fitting the models, and generating the counts/rankings. Add the actual code and captured intermediate outputs, or label these comparisons as unverifiable rather than presenting them as executed evidence.

## P1 — repeated_count_concern

Saved da-13-6/rep-003/s003. Decision **accept**, 0 concerns. Flags: none confirmed.

Both candidates return no_issue. No new demand to change reconciled counts.

Current 212=167+45 and distinct joint-FDR denominators are retained.

Public source spans: 95–123, 208–236. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P1 — corrective_learned_check

Saved da-13-6/rep-003/s001. Decision **revise**, 2 concerns. Flags: none confirmed.

Retains a useful question about outcome-dependent smaller-p selection and asks for non-selection-based sensitivity. A generic rerun request lacks a specific numerical contradiction; lack of a raw log alone is not proof the reported outputs were not computed.

Scientific caution about headline concordance after per-protein selection survives from public evidence without receiving the selected requirement as a new private channel.

Public source spans: 97–121, 176–208. Exact excerpts and native paths are in [JSON](feedback-review.json).

> Please rerun the complete analysis from the supplied CSVs and verify that the selected-MHT counts, correlations, and displayed protein signs reproduce the reported values. The trace adds selection code, but the cited output values are presented without captured execution output, so their numerical correctness remains unverified.

> Please verify that the selected-overall MHT comparison is scientifically appropriate: choosing the smaller adjusted p-value separately for each protein across age strata is data-driven and may inflate apparent overlap. Recompute or report a sensitivity analysis using a pre-specified single age stratum or another non-selection-based summary before presenting 80.3% and 90.5% as the headline concordance.

## P1 — proactive_label_substantive_check

Saved da-13-6/rep-001/s004. Decision **accept**, 0 concerns. Flags: none confirmed.

Both candidates return no_issue. No host origin-tag rewrite was used.

Current arithmetic and explicit reporting resolve the cited implementation/accounting concerns; absence of all possible issues is not established.

Public source spans: 101–119, 143–158, 179–207. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P1 — proactive_only_request

Saved da-18-5/rep-001/s001. Decision **revise**, 2 concerns. Flags: D.

Claims there is no explicit cohort-definition step with intermediate counts, although Step 1 provides filters, prints and cohort counts. A generic rerun request is not evidence an execution failed. Additional identifier/missingness checks could be useful, but should not be framed as absence of the displayed cohort step.

Asks to verify CNA lookups/union rather than supplying a hidden expected event count. This fixture is not a verified error-free accept oracle.

Public source spans: 13–39, 47–71, 92–109. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The trace does not include a required explicit Approach step documenting the cohort-definition data-quality checks and intermediate filtering counts at each stage; it jumps from loading and selecting cohorts to event construction. Add a reproducible validation step with the actual checks and counts (including identifier matching and missingness) before the event analysis.

> Please verify the reported intermediate counts by rerunning the embedded code against the supplied files, particularly the CNA row lookups and the stated 99/687 union and ESR1 contingency table; the trace provides code and outputs but no execution log establishing that these exact values were produced.

## P1 — unmet_base_requirement

Saved da-15-1/rep-001/s000. Decision **revise**, 3 concerns. Flags: none confirmed.

Method validation is useful. Issue 3 requests recomputation/ordering verification despite the shared loc[sample_ids] ordering; a mismatch is not established, but the request to add an assertion is not counted as a definite false factual claim. First concern ends with a malformed partial word, exactly as generated.

RNA-seq variance/sensitivity validation remains useful. Asking for an explicit ordering assertion is acceptable as a check, not evidence the displayed indexing is inconsistent.

Public source spans: 29–45, 63–87, 105–111. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The analysis uses OLS on log2(CPM+0.5) with unmoderated gene-wise variance estimates for 21,232 genes, despite the count data being RNA-seq and the groups being highly imbalanced (138 ALS versus 36 controls). This can yield anticonservative p-values and plausibly explains the extraordinarily large result set (11,244 significant genes). Reanalyze with a validated count-based model such as DESeq2/edgeR, including the stated covariates and appropriate filtering, then report the revised effect sizes and FDRs; if retaining OLS, provide diagnostic or sensitivity analyses demonstrating calibrated/inﬂ

> The trace does not provide the required per-step quantitative intermediate results for the reported results-generation operations: it shows code printing the top 50 genes and writing `de_results.csv`, but does not include the resulting ranked tables or the complete significant-gene output. Add the actual generated results (or a clearly referenced output file) so the reported gene list and statistics are inspectable and reproducible.

> Recompute the reported differential-expression results: the OLS code uses `meta` row order for the design matrix, but `Y` columns are ordered by `sample_ids` from count columns. Although metadata is selected with `.loc[sample_ids]`, the count matrix is then subset using `sample_ids` while `Y` is iterated independently; verify that `meta.rna_id` exactly equals the count-matrix column order and add an explicit assertion before fitting. Also verify the reported 11,244 significant genes and top-gene statistics from the saved output, since these values are not independently shown by the trace.

## P1 — cohort_scope_ambiguity

Saved da-18-5/rep-001/s000. Decision **revise**, 3 concerns. Flags: none confirmed.

Raises the real non-naive-versus-post-hormonal exposure ambiguity and broad mutation/CNA event rule. TUMOR_TISSUE_ORIGIN alone is not proven to encode actual therapy exposure, so a mandatory replacement column is stronger than the public evidence supports.

Scope verification, functional-event justification and specific references are useful; no hidden gene-set answer is supplied.

Public source spans: 17–39, 41–71, 117–132. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The cohort is defined using `SAMPLE_SITE != Treatment Naive Primary`, but the task identifies post-treatment exposure with `TUMOR_TISSUE_ORIGIN` and distinguishes metastatic samples from post-treatment primary tumors. This operationalization may include metastatic samples without documented post-hormonal exposure and should be replaced or explicitly validated against `TUMOR_TISSUE_ORIGIN`; recompute the denominator and frequency for the correctly defined post-hormonal-therapy cohort.

> The MAPK alteration rule counts every mutation record in the selected genes, without filtering Variant_Classification for qualifying somatic alterations. Because the MAF includes classification fields and the question asks for pathway alterations, verify and restrict mutation calls to an explicitly justified set of functional variant classes (and report the resulting recomputed numerator and frequency); otherwise passenger, silent, or non-functional records may inflate the 93-sample union.

> The trace includes references, but it does not provide an identifiable citation supporting the specific MAPK gene-set definition or the biological interpretation of those genes as pathway alterations. Add a checkable source for that method choice, or explicitly state that the gene set is an operational analysis definition rather than a literature-derived canonical set.

## P1 — sensitivity_verification

Saved da-15-1/rep-002/s007. Decision **revise**, 2 concerns. Flags: D.

Two independent renders falsely say repeated fit_run writes leave only the final run or that aggregation is absent. Line 156 writes DataFrame(rows) after the loop. One render also catches the real dc/disease_col mismatch. Neither catches the rowwise sign comparison after independently sorting results.

Variable-name repair survives but is bundled with a false overwrite allegation; output is preserved unchanged, including a truncated ending.

Public source spans: 60–63, 103–106, 138–156, 171–175. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The sensitivity loop is not fully authoritative: each `fit_run` call writes `nb_diagnostics.tsv`, so the final file is overwritten repeatedly and the trace does not show the complete implementation that safely aggregates per-run diagnostics. Also, the reported sensitivity values cannot be independently reconciled from the displayed code because `fit_run` uses `dc` while the setup defines `disease_col`. Use one consistent variable name, return diagnostics without overwriting inside each run, write the aggregated table once after all runs, and ensure the reported values are generated by that one

> The diagnostic code writes `nb_diagnostics.tsv` inside every `fit_run` call, so each sensitivity run overwrites the prior diagnostics; the final file contains only the last run unless an additional aggregation step is shown. Also, the documented sensitivity loop itself is present, but the trace does not show the resulting five-row file or a check that the final diagnostics and primary result file correspond to the same run. Accumulate diagnostics in memory and write once after all runs, then report or include the resulting rows and verify that `de_results.tsv` is written only for the primary.

## P1 — partial_analysis_method

Saved da-15-1/rep-003/s001. Decision **revise**, 3 concerns. Flags: none confirmed.

Retains failed-fit accounting but mixes it with an unsupported normalization-order suspicion. Source code already uses normalized mu for dispersion. Does not flag the displayed doubled chi-square tail. Second concern ends in malformed generated text; no host truncation/repair applied.

Public mismatch between reported failed fits and a loop lacking handling is real. Need for scientific validation is distinct from requiring a specific package.

Public source spans: 43–76, 102–125. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The displayed code computes size factors from all genes before applying the expression filter, and its negative-binomial GLM uses the raw counts with a size-factor offset but does not visibly normalize the gene-specific mean/dispersion calculation consistently. Please verify the implementation against a known count-based workflow and recompute the reported DE counts and rankings, including handling of genes whose fits failed or hit the dispersion cap.

> The trace does not provide a fully reproducible primary analysis: it says sparse/zero-heavy fits failed, but the code has no exception handling or reporting of how many genes failed, and it does not show the actual failed-gene exclusions. Also, the median-ratio size factors are calculated before the count filter and then retained, while the reported primary results are not accompanied by a complete output table or code that verifies the displayed gene statistics. Record failed-fit counts and identities, define the exact analyzed gene set, and save/report the complete primary results so the 3,憲

> The biological interpretation invokes activated microglial/macrophage, lysosomal, myelin, and mitochondrial programs, but the listed references do not directly support these specific ALS spinal-cord claims (the cited Mathys et al. paper is Alzheimer’s single-cell data). Add checkable ALS-relevant references for these interpretations, or explicitly label them as data-derived exploratory interpretations rather than literature-supported mechanisms.

## P2 — private_target_counts

Saved da-13-6/rep-002/s000. Decision **revise**, 2 concerns. Flags: none confirmed.

No private protein examples or expected conclusion. Verifier 2 overstates separate comparator analyses as pooling; renderer downgrades to a public comparability question rather than asserting a wrong numerical answer.

Public references/documentation request and verification of cross-model comparability survive. No claim that zero named leakage proves general immunity.

Public source spans: 37–64, 93–111. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The trace's biological interpretation and Olink methodological claims are not supported by real, identifiable citations: the Olink entry is only a generic documentation label, and no citations are tied to the mechanisms invoked. Replace it with checkable references (or remove unsupported external claims) and explicitly connect each substantive biological claim to its source.

> Please verify that the Table 7 estimates being correlated are sufficiently comparable across their distinct populations, exposure definitions, age strata, and effective sample sizes. If not, stratify or otherwise harmonize the comparisons, or present the correlations and significance-overlap counts only as exploratory—not as evidence of proteomic consistency.

## P2 — different_populations

Saved da-13-6/rep-003/s002. Decision **accept**, 0 concerns. Flags: none confirmed.

All three candidates are rejected as unsupported. Verifier explicitly distinguishes primary all-GAHT-significant denominators, exploratory selection, and joint-FDR sensitivity.

Correctly avoids forcing a repeated population/count correction on the current artifact.

Public source spans: 97–120, 199–209, 219–227. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — coefficient_coding_sign

Saved da-15-1/rep-002/s001. Decision **revise**, 3 concerns. Flags: B.

Verifier 1 and renderer 1 incorrectly say the prose calls the raw disease_Control coefficient ALS-minus-Control. The prose states the intended disease contrast; negating the Control dummy implements it. This is a false internal-inconsistency allegation, not literally the old claim that negation reverses the contrast. Historical changes in gene counts do not themselves establish a current contradiction.

Other concerns retain the real scalar-WLS defect and request a public summary of negative effects; do not dismiss those because the sign concern is false.

Public source spans: 53–81, 92–116. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The documented contrast is internally inconsistent: the model uses the `disease_Control` coefficient, yet the prose calls that coefficient “ALS minus Control” while the code negates it to report `log2FC_ALS_vs_control`. Explicitly verify the encoding and sign convention, then recompute or correct all reported effect directions and leading-gene values; also expose the generated ranked result table so the revised 30,168-gene/7,029-significant claims are auditable.

> The Results and final answer do not display the complete set of differentially expressed genes or a summary of downregulated/significant genes; they only list selected upregulated examples and defer the negative effects to `de_results.tsv`. Add a checkable summary table or complete gene list, including effect direction, log2FC, p-value, and FDR, while retaining the full ranked output.

> The revised code is not a standard negative-binomial GLM or limma-voom analysis: it applies one scalar, method-of-moments-derived weight per gene to log2-transformed normalized counts and uses fixed t degrees of freedom. Refit with a validated RNA-seq method (edgeR/DESeq2 or limma-voom), then recompute and report the statistics, FDRs, rankings, and DEG counts; do not present the current NB-derived values as the requested RNA-seq-specific result.

## P2 — unavailable_remedy

Saved da-15-1/rep-003/s003. Decision **revise**, 3 concerns. Flags: none confirmed.

Three independent renders converge on substantially the same package/method concern, rather than retaining the specific missing sensitivity-code check. Conditionals avoid asserting availability, but repeated package-only demands and withdrawing the primary answer remain oversteering risks.

The WLS validity concern is real; current outputs are openly qualified. Missing executable sensitivity code is a missed useful local check.

Public source spans: 41–67, 75–107, 140–150. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The primary results still rely on a custom method-of-moments WLS approximation rather than a validated RNA-seq framework. Reanalyze with an actually available DESeq2, edgeR, or limma-voom implementation (install one if permitted), then recompute and report all DEG counts, FDRs, fold changes, and rankings from that model; otherwise clearly withhold these approximate results as answers to the requested differential-expression analysis.

> The reported DEG counts, FDRs, fold changes, and rankings still come from an explicitly unvalidated method-of-moments WLS approximation rather than DESeq2, edgeR, or limma-voom. Recompute these results with a validated RNA-seq framework if the environment permits; otherwise report that the requested rigorous analysis remains incomplete and do not present the exploratory figures as the primary answer.

> The reported DEGs, FDRs, fold changes, and sensitivity results still come from a custom method-of-moments WLS approximation, not a validated RNA-seq framework. Reanalyze with an available validated DESeq2, edgeR, or limma-voom implementation (install one if permitted), and recompute all reported results; otherwise clearly withhold these approximate statistics as definitive findings.

## P2 — repeated_count_concern

Saved da-13-6/rep-003/s003. Decision **accept**, 0 concerns. Flags: none confirmed.

Three verifiers reject stale inconsistency/implementation/documentation concerns. They explicitly compute the sums and separate joint-FDR denominators.

Correctly rejects the old fabricated 167-availability reading.

Public source spans: 95–123, 208–236. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — corrective_learned_check

Saved da-13-6/rep-003/s001. Decision **accept**, 0 concerns. Flags: none confirmed.

Both candidates rejected; verifier treats implementation of the selected endpoint as sufficient and overlooks the methodological value of a non-selection-based primary comparison. This is a concern-retention weakness, with severity less definite than the executable defects in sensitivity_verification.

The unchanged separate learned reminder would still be available in a trajectory; no solver exposure occurred in this diagnostic.

Public source spans: 97–121, 176–208. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — proactive_label_substantive_check

Saved da-13-6/rep-001/s004. Decision **accept**, 0 concerns. Flags: none confirmed.

Three verifiers return unsupported after recognizing current code, assertions and reconciled tables.

Accept is the public review outcome, not suppression based on a proactive label.

Public source spans: 101–119, 143–158, 179–207. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — proactive_only_request

Saved da-18-5/rep-001/s001. Decision **accept**, 0 concerns. Flags: none confirmed.

Both candidates rejected; current event definitions and public outputs recognized. The verifier accepts the disclosed metastatic/post-therapy operational assumption; this does not establish the assumption scientifically matches every task exposure.

No proactive tag forces revise or host accept. Scope uncertainty remains, so accept is not labeled a proven globally correct verdict.

Public source spans: 13–45, 92–122. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — unmet_base_requirement

Saved da-15-1/rep-001/s000. Decision **revise**, 3 concerns. Flags: none confirmed.

Retains method verification and correctly notices CD68 is in the final answer but absent from the trace positive list. The proteomics concern is conditional on actual availability; the task background mentions that dataset but the listed local inputs do not include it.

The CD68 reconciliation request is grounded in public text, not private named-answer guidance; it is a verification request, not proof CD68 is not differential.

Public source spans: 9–16, 105–128. Exact excerpts and native paths are in [JSON](feedback-review.json).

> Please verify the genome-wide findings with an RNA-seq count-based method such as DESeq2, edgeR, or limma-voom, or provide residual/dispersion diagnostics and a sensitivity analysis supporting the log2(CPM+0.5) OLS approach. The unusually large fraction of significant genes makes this validation important before relying on the reported list.

> Please verify whether the supplied Oeckl et al. proteomics data were available in the execution environment. The task describes them as part of the dataset for orthogonal validation, while the trace says no proteomics file was supplied and performs no protein-level validation. If accessible, incorporate and document the validation; otherwise explicitly document the unavailable input as a task limitation.

> Please verify the reported rankings and gene lists by preserving the complete significant-results table (or a checksum-backed output) and confirming the discrepancy where CD68 appears in the final answer but not in the trace's displayed top-50 positive list.

## P2 — cohort_scope_ambiguity

Saved da-18-5/rep-001/s000. Decision **revise**, 3 concerns. Flags: none confirmed.

Twice retains the real missing sensitivity-union code and once the broad event-definition issue. One renderer offers labeling as independently verified as an alternative to code; that wording is insufficient without actual verification. Duplicate requests consume slots.

Shown alternate-cohort code never computes the claimed 82 altered/11.63% result. Counts come from the public artifact, not a private target.

Public source spans: 41–71, 99–121. Exact excerpts and native paths are in [JSON](feedback-review.json).

> The sensitivity-check step reports 82 altered samples and 11.63%, but its code only constructs and prints the 705-sample cohort; it does not recompute mutations, CNAs, the union, or the percentage. Add copy-pasteable code and intermediate results for the full sensitivity analysis, or label the reported result as an independently verified check rather than a trace-reproducible computation.

> The analysis counts every mutation and non-neutral CNA in selected genes as a MAPK alteration, without defining or filtering for activating/pathogenic events. This makes 12.2% a broad genomic-event frequency rather than a defensible frequency of MAPK pathway activation. Define a justified alteration rule using the available variant annotations and CNA context, recompute the union, or explicitly relabel the result as the frequency of any selected-gene genomic event.

> The sensitivity check reports 82 MAPK-altered samples and 11.63% but only shows code constructing the alternate cohort; it does not recompute alterations or the percentage. Add copy-pasteable code and intermediate counts for the full sensitivity calculation, or label those values as an unverified comparison.

## P2 — sensitivity_verification

Saved da-15-1/rep-002/s007. Decision **accept**, 0 concerns. Flags: D,E.

All three verifiers reject the candidates and the pipeline accepts. Verifier 2 claims variable names were reconciled, but setup defines disease_col and the function reads dc. Both result tables are independently sorted/reset before positional sign comparison. These two concrete executable defects are lost.

Correctly avoids the false overwrite allegation, at the cost of suppressing useful local corrections. Lower concern count is not success.

Public source spans: 60–63, 103–106, 138–156, 171–175. Exact excerpts and native paths are in [JSON](feedback-review.json).

## P2 — partial_analysis_method

Saved da-15-1/rep-003/s001. Decision **revise**, 3 concerns. Flags: D.

Retains validation/failed-fit concerns. Verifier 3 and renderer 3 say dispersion-cap handling is not shown, although alpha=min(max(...),10) is explicit. Pre-filter size-factor estimation is not intrinsically invalid. Also misses the doubled chi-square tail.

Failed-fit accounting survives; the code-level p-value defect is a missed opportunity in both candidates, not a claim that all other concerns are useless.

Public source spans: 43–76, 102–125. Exact excerpts and native paths are in [JSON](feedback-review.json).

> Please independently verify the reported primary DE counts and p-values with a standard RNA-seq count framework such as DESeq2, edgeR, or limma-voom, or document validation of this custom negative-binomial implementation, including failed-fit handling and dispersion/size-factor choices. The current method uses gene-wise method-of-moments dispersions, arbitrary caps, and acknowledges sparse-fit failures, so its primary inference remains uncertain.

> The primary count-model results are not fully reproducible from the shown code: size factors are computed using all 58,884 genes before the stated count filter, and the loop provides no exception handling or accounting for failed fits even though the text says some fits failed. Recompute normalization on the defined analysis set (or justify the alternative), explicitly record excluded genes, and ensure BH correction and reported totals use the documented tested-gene denominator.

> The trace does not provide copy-pasteable code for several claimed operations and results: model-failure/dispersion-cap handling, quantitative batch/QC assessments, and the full pre-filter-to-post-filter dimension check. Add the actual executed code and corresponding intermediate outputs so the required analysis is reproducible.

